Advertisement
UK markets open in 3 hours 7 minutes
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • HANG SENG

    18,394.71
    +187.58 (+1.03%)
     
  • CRUDE OIL

    79.22
    +0.27 (+0.34%)
     
  • GOLD FUTURES

    2,310.20
    +0.60 (+0.03%)
     
  • DOW

    38,225.66
    +322.37 (+0.85%)
     
  • Bitcoin GBP

    47,636.75
    +1,845.84 (+4.03%)
     
  • CMC Crypto 200

    1,286.18
    +15.43 (+1.21%)
     
  • NASDAQ Composite

    15,840.96
    +235.48 (+1.51%)
     
  • UK FTSE All Share

    4,446.15
    +27.55 (+0.62%)
     

Carisma Therapeutics to Present at Upcoming Conferences

PHILADELPHIA, April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at the following upcoming conferences:

(PRNewsfoto/CARISMA Therapeutics Inc.)
(PRNewsfoto/CARISMA Therapeutics Inc.)

Needham 23rd Annual Virtual Healthcare Conference

  • Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.

  • Wednesday, April 10 at 3:45 PM ET

  • Virtual

Chardan 8th Annual Genetic Medicines & Cell Therapy Manufacturing Summit

  • Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.

  • Monday, April 29 at 2:00 PM ET

  • Virtual

ADVERTISEMENT

Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts, when available, will be archived for a limited time following each event.

About Carisma 

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com

Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-conferences-302106448.html

SOURCE Carisma Therapeutics Inc.